EP1697743B1 - Tube pour plasma a la demande - Google Patents

Tube pour plasma a la demande Download PDF

Info

Publication number
EP1697743B1
EP1697743B1 EP04814676A EP04814676A EP1697743B1 EP 1697743 B1 EP1697743 B1 EP 1697743B1 EP 04814676 A EP04814676 A EP 04814676A EP 04814676 A EP04814676 A EP 04814676A EP 1697743 B1 EP1697743 B1 EP 1697743B1
Authority
EP
European Patent Office
Prior art keywords
collection chamber
primary
tube
primary collection
porous filter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP04814676A
Other languages
German (de)
English (en)
Other versions
EP1697743A1 (fr
Inventor
Dimitrios Manoussakis
Robert J. Losada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Becton Dickinson and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co
Publication of EP1697743A1 publication Critical patent/EP1697743A1/fr
Application granted granted Critical
Publication of EP1697743B1 publication Critical patent/EP1697743B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/56—Labware specially adapted for transferring fluids
    • B01L3/563—Joints or fittings ; Separable fluid transfer means to transfer fluids between at least two containers, e.g. connectors
    • B01L3/5635—Joints or fittings ; Separable fluid transfer means to transfer fluids between at least two containers, e.g. connectors connecting two containers face to face, e.g. comprising a filter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0681—Filter
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
    • B01L2400/049—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics vacuum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5082—Test tubes per se

Definitions

  • the present invention relates to separation of plasma from whole blood.
  • the present invention relates to a medical device capable of separating plasma from agglutinated blood cells through a porous filter membrane.
  • Plasma is the liquid portion of blood primarily comprised of water.
  • the water portion of the plasma is freely transferable with cells of the body and other extra cellular fluids.
  • Plasma is also comprised of salts, glucose, amino acids, vitamins, hormones and metabolic waste products.
  • plasma provides the means to suspend white blood cells, red blood cells and other cellular components for transfer through a human or animal. If a plasma sample is desired, separation from the other cellular components of blood must occur well before coagulation of the blood. Once the blood coagulates, serum is the remaining liquid portion of the collected blood sample, which is devoid of some protein components of blood.
  • plasma contains a rich source of components available for diagnostic analysis
  • medical devices are available for use in separating plasma from a whole blood sample.
  • evacuated multi-chamber devices which incorporate a filter used to yield plasma removed from a collected blood sample.
  • the devices use a detachable chamber, allowing a user to access the separated plasma specimen.
  • the prior art devices typically use a filter membrane having small and fine pore sizes to prevent cellular components from passing therethrough, which can render the vacuum forces generated by the evacuated device inadequate to drawn plasma from a collected blood sample.
  • Ishimito et al. disclose a blood separating tube in United States Patent No. 6,506,167 entitled, "Blood-Collecting Tubes," including an upstream tube separated by a filter from a downstream tube where the tubes are attachable to and detachable from each other and are evacuated.
  • Blood is removed from a patient through intravenous puncture and transferred into the upstream tube through blood pressure and negative pressure inside the tube.
  • a pressure differential is supposed to be created between the upstream tube and the downstream tube as the blood contacts the filter between the two tubes.
  • filters include a membrane, glass fibers, filter paper with large pores having attached thereto anti-hemocyte antibodies, a filter impregnated with a cationic macromolecular substance to aggregate cells, and a laminated multilayer filter.
  • Problems that exist with this disclosure are blood cells clogging the filter and an inadequate vacuum force between the upstream tube and downstream tube during blood collection.
  • a further problem that exists with this disclosure is exposing any plasma collected in the downstream tube to contaminants should the downstream tube be removed from the upstream tube.
  • Konrad in United States Patent Application Publication No. 2003/0013205 , entitled “Separating Device,” describes a preferred method of producing a concentration of nucleic acids, RNA or DNA, from whole blood by way of a liquid-permeable separating element.
  • the separating elements disclosed include filters, silicate membranes, ion-exchange membranes and columns or separating columns. It is disclosed that the invention is capable of causing the release of nucleic acid molecules from the cellular components of the blood through lysis.
  • the collected sample containing lysed blood cells is passed through a separating element, which is capable of adsorbing the nucleic acid component.
  • the separating element can be removed for later molecular diagnostic analysis. Konrad does not disclose plasma separation from whole blood.
  • Murto et al. in World Intellectual Property Organization International Publication No. WO 02/29406 entitled “Methods and Devices for Processing Blood Samples,” describes methods and related devices and reagents for separating plasma from a whole blood sample.
  • the invention as disclosed describes a method of separating plasma from the cellular components of whole blood by mixing a reagent comprising magnetically attractable particles having an agglutinating agent bound thereto with a whole blood sample.
  • the purpose of the magnetic reagent is to bind the cellular components of the whole blood sample.
  • a magnetic force is then applied to the mixture to separate the magnetic reagent with cells bound thereto from the plasma.
  • the plasma is separated from the mixture by pipetting, decanting, siphoning or wicking.
  • the present invention is directed to a device for separating plasma from whole blood, including a primary collection chamber having a blood agglutinating agent and an anticoagulant deposited therein, and a porous filter separating the primary collection chamber from a secondary collection chamber.
  • a transfer device having at least one needle may be provided to transfer plasma from the primary collection chamber to the secondary collection chamber.
  • the invention is an improvement over the prior art as it is capable of providing sufficient force by the vacuum in the evacuated tubes to separate plasma from agglutinated, but uncoagulated, blood cells with a large pore filter that is less prone to clogging with aggregated blood cells.
  • the use of an agglutinating agent to aggregate the cells, in combination with a filter having a larger pore size, permits separation of plasma from the aggregated cells with the use of conventional evacuated tubes, which, because of this combination, have adequate vacuum to draw the plasma through the filter.
  • the invention is a further improvement over the prior art as it is easy to use in clinical and research applications.
  • the invention is an even further improvememt over the prior art as it is capable of providing an uncontaminated plasma specimen that is separated from a whole blood sample.
  • an agglutinating agent alone which causes the cells present in the sample to aggregate together.
  • the cells themselves can be considered the "starting particles" to which additional cells will stick or aggregate.
  • a structure coated with an agglutinating agent can be used, and the coated structures are the starting particles, to which the cells stick or aggregate.
  • the primary collection chamber is provided in an evacuated collection tube hermetically sealed with a pierceable rubber stopper.
  • a vent needle which is gas permeable, is optionally provided that may be inserted through the pierceable rubber stopper.
  • An agglutinating agent is present within the primary collection chamber to aggregate blood cells in a whole blood sample that is collected within the primary collection chamber.
  • an anticoagulant may coat the surface of the internal wall of the primary collection chamber to prevent coagulation of the whole blood sample collected within the primary collection chamber.
  • a transfer device is further provided in the form of a cylinder with a hollow partition internally attached within the device.
  • the interior walls of the cylinder and the partition define an upstream chamber and a downstream chamber.
  • a porous filter which is capable of separating plasma from aggregated blood cells, is held within the hollow partition.
  • Two needles are mounted in the partition surface, whereby the needles are positioned on opposing sides of the filter. The two needles provide fluid communication into and out of the hollow partition through the filter.
  • blood can enter the hollow partition at the upstream end of the transfer device, with plasma passing through the porous filter, through the downstream end and out of the transfer device into a secondary chamber.
  • the secondary chamber is desirably a secondary tube having an evacuated collection tube hermetically sealed with a pierceable rubber stopper.
  • the primary collection chamber is provided as an evacuated, double-ended collection tube hermetically sealed at both ends with pierceable rubber stoppers.
  • a cylindrical porous filter is secured within the primary collection chamber whereby the porous filter lies adjacent to and abuts against an annular shoulder of a pierceable rubber stopper.
  • a vent needle which is gas permeable, is optionally provided that may be inserted through the pierceable rubber stopper sealed at the upstream end of the primary collection chamber.
  • the primary collection chamber is provided in an evacuated collection tube that is hermetically sealed with a pierceable rubber stopper.
  • a cylindrical porous filter having a central bore through the length of the filter is secured within the primary collection chamber at a location adjacent the pierceable rubber stopper end of the collection tube.
  • a rubber one-way valve is attached to the porous filter at one end of the central bore, thereby sealing the bore. The one-way valve allows whole blood being collected to flow into the primary collection chamber.
  • a vent needle which is gas permeable, is optionally provided that may be inserted through the pierceable rubber stopper.
  • An alternate transfer device for use with such embodiments of the collection tube, which includes a cylinder including an internal solid partition attached therein.
  • the partition separates the cylinder into an upstream chamber and a downstream chamber, defined within the interior walls of the cylinder.
  • a double-ended needle is mounted through the partition, whereby the needle extends perpendicular to the surfaces of the partition, and provides fluid communication through the partition of the transfer device between the upstream and downstream chambers.
  • a secondary chamber such as a secondary evacuated tube sealed with a rubber stopper, can then be inserted within the downstream chamber and pierced by the downstream end of the needle, with plasma flowing through the filter and through the transfer device, into the secondary chamber of the secondary evacuated tube.
  • a double-ended collection tube that is hermetically sealed at both ends with pierceable rubber stoppers.
  • a cylindrical porous filter is secured between the two ends of the tube, desirably at a location that is equidistant from each end of the double-ended collection tube.
  • the porous filter provides a separation defining a primary collection container and a secondary chamber within the single tube.
  • An agglutinating agent and an anticoagulant are present within the primary chamber of the tube. As such, blood collected within the primary chamber is contacted with these agents, causing the cells to aggregate.
  • Negative pressure within the secondary chamber can then draw the plasma through the filter into the secondary chamber, where it can thereafter be further transferred to a separate container, such as through a separate transfer device attached with an additional collection tube piercing the stopper at the secondary chamber downstream end of the tube.
  • a vent needle which is gas permeable, is optionally provided that may be inserted through the pierceable rubber stopper at the upstream end of the tube to access the primary collection chamber during use.
  • FIGS. 1-3 illustrate an assembly for separating plasma from whole blood.
  • the present invention is generally described in terms of a blood collection and plasma separation device 10, which is defined generally by primary tube 24 enclosing primary collection chamber 38, secondary tube 124 enclosing secondary collection chamber 138, and transfer device 54 housing porous filter 72.
  • the purpose of the present invention is to separate plasma from the cellular components of blood by exposing blood in a primary collection chamber such as a primary tube to an agglutinating agent to create large aggregates of blood cells. Then, a pressure differential is used to draw the mixture of aggregate blood cells and plasma into a porous filter, whereby the aggregate blood cells become trapped and a difference in pressure between the primary collection chamber and a secondary collection chamber, such as a secondary tube, continues to draw the plasma through the porous filter into the secondary collection chamber.
  • the primary tube can be used with any medical device capable of either collecting blood directly from a patient or indirectly from a previously collected blood sample, such as any blood collection device that includes a piercing element or allows for attachment to a catheter.
  • upstream and downstream are used in reference to the assembly of the invention while in use, which is when the primary tube and secondary tube are connected to the transfer device during plasma transfer.
  • upstream and downstream are relative terms used in reference to plasma flow from upstream in the primary collection chamber to downstream in the secondary collection chamber during use.
  • anticoagulant is used to describe any compound known in the art, such as heparin, capable of preventing blood coagulation.
  • primary tube 24 comprises tube 26 hermetically sealed with rubber stopper 42.
  • Tube 26 includes generally cylindrical tubular wall 28 extending between closed end 30 and open end 32.
  • Tube 26 has interior surface 34 and exterior surface 36.
  • Tube 26 is comprised of a suitable material, which is impermeable to gas and liquid, and is desirably made of glass or molded plastic.
  • Rubber stopper 42 is an elastomeric closure which is comprised of a suitable material capable of providing open end 32 of tube 26 with a gas- and liquid-tight seal, and capable of being punctured or pierced with an appropriate medical device, such as a needle, for transfer of blood into tube 26.
  • Rubber stopper 42 includes a main portion 46 centrally molded with depending portion 50. Depending portion 50 extends from main portion 46, with depending portion 50 capable of extending into open end 32 of tube 26. Depending portion 50 may be annular, having cavity 52. Rubber stopper 42 may include top surface 44 with depending recess 48 centrally molded or fabricated thereon.
  • Tube 26 is an evacuated tube, in that the interior space within tube 26, which defines primary collection chamber 38, has a negative pressure or a reduced pressure relative to the respective ambient pressure, such as compared with blood pressure or with atmospheric pressure. In this manner, a type of vacuum can be established within tube 26 to draw fluid therein from an external environment, as is well known in the art.
  • agglutinating agent 12 Prior to evacuating tube 26 and hermetically sealing circumferential surface 49 of depending portion 50 of rubber stopper 42 to interior surface 34 of tube 26, interior surface 34 of tube 26 may be coated with anticoagulant 14.
  • An agglutinating agent 12 is then deposited inside tube 26.
  • Such agglutinating agent 12 may be any compound that is capable of binding blood cells suspended in whole blood to create large aggregates of blood cells. Examples of specific agglutinating agents include lectins, such as potato or wheat lectins. Alternative agglutinating agents may include antibodies with an affinity for blood cells attached to microbeads.
  • the agglutinating agent may be in the form of a solution, pellet, pill, or lyophilized specimen, such as granules.
  • agglutinating agent is used to denote the use of an agglutinating agent alone to form cell aggregates, or the use of an agglutinating agent in combination with a structure that can impart desired properties to the cellular aggregates.
  • the structure can be specially designed to have specific desired properties.
  • the structure can be a microbead of a particular density, coated with an agglutinating agent. If it is desired to have the aggregated cells float on top of the sample, a bead having a lower density than that of plasma can be used, such that when aggregated on the beads, the aggregated cells float on top of the sample, thereby preventing clogging of the filter and permitting the plasma to pass.
  • the structure can have a specific geometry, such as a string or cylinder, to impart a desired shape to the aggregates, such as a shape that is less densely packed than cellular aggregates without the structure, and which permits plasma to pass through the aggregates.
  • the specific geometry and shape of the structure can also be designed to maintain the aggregated particles away from the filter, thereby more easily permitting the plasma to pass therethrough without clogging.
  • agglutinating agent will refer to the use of an agglutinating agent alone, or in combination with a structure as described above, which has been coated with an agglutinating agent.
  • Agglutinating agent 12 is housed in primary collection chamber 38 of primary tube 24 once tube 26 is evacuated and hermetically sealed.
  • a secondary tube 124 is further provided including cylindrical tubular wall 128 extending between closed end 130 and open end 132 in a similar manner as with primary tube 24. Secondary tube 124 is evacuated and hermetically sealed at open end 132 with a conventional rubber stopper 142, similar to stopper 42.
  • the secondary tube 124 can be any blood collection tube known in the art comprised of glass or plastic matrix. Interior surface 134 of secondary tube 124 hermetically sealed with rubber stopper 142 defines secondary collection chamber 138.
  • Device 10 further includes a transfer device 54 for transfer of plasma from primary tube 24 to secondary tube 124, as will be discussed in more detail herein.
  • Transfer device 54 is comprised of tubular plastic cylinder 56 having hollow partition 62 internally therein, and desirably spaced equidistant from the opposing ends of cylinder 56.
  • Cylinder 56 has exterior surface 58 and interior surface 60, with an internal diameter that is larger than the diameter of primary tube 24 and secondary tube 124.
  • Partition 62 is comprised of upstream convex disk 64 and downstream convex disk 66, both desirably molded during manufacture to interior surface 34 of cylinder 56.
  • the exterior surfaces of partition 62 and interior surface 60 of plastic cylinder 56 define upstream chamber 74 and downstream chamber 76 of transfer device 54.
  • the interior surfaces of convex disks 64, 66 define space 70, which houses porous filter 72.
  • Porous filter 72 is a filter matrix including pores which are sufficiently large enough to draw plasma therethrough under a normal vacuum of a conventional evacuated blood collection tube, but sufficiently small and including a long filtration path so as to catch and retain blood cell aggregates.
  • porous filter 72 is comprised of a high-density polyester or polypropylene, sintered plastic, glass fibers or any other material capable of creating a porosity size of equal to or greater than 10 microns. Variations of the structural shape of the porous filter are contemplated within the preferred embodiments.
  • Upstream needle 78 and downstream needle 82 are mounted in upstream convex disk 64 and downstream convex disk 66 of hollow partition 62, respectively, and point in opposite directions relative to each other.
  • Upstream needle 78 is positioned within upstream chamber 74 of transfer device 54 and downstream needle 82 is positioned within downstream chamber 76 of transfer device 54 and are centered within interior surface 60 of cylinder 56.
  • Upstream needle 78 provides fluid communication through upstream convex disk 64 to porous filter 72
  • downstream needle 82 provides fluid communication through downstream convex disk 66.
  • Elastomeric needle sheaths 86, 88 are provided to cover upstream needle 78 and downstream needle 82, respectively, as known in the art. Elastomeric needle sheaths 86, 88 are flexibly slidable along needles 78, 82. Elastomeric needle sheaths 86, 88 act as a valve, provide means for an airtight seal between both needles 78, 82 during insertion of either needle 78, 82 through rubber stoppers 42, 142 hermetically sealed to primary tube 24 and secondary tube 124, respectively.
  • the length of cylinder 56 provides a safety measure, whereby tip 80 of upstream needle 78 covered by needle sheath 86 is completely contained within upstream chamber 74 of transfer device 54 and tip 84 of downstream needle 82 covered by needle sheath 88 is completely contained within downstream chamber 76 of transfer device 54.
  • primary tube 24 is used in a standard phlebotomy procedure to collect blood in primary collection chamber 38 through standard intravenous collection practices.
  • the reduced pressure established through the evacuated primary collection chamber 38 decreases as the volume of blood in primary collection chamber 38 increases.
  • the blood contacts agglutinating agent 12 deposited therein and anticoagulant 14 coated on interior surface 34 of tube 26.
  • Anticoagulant 14 prevents the blood from forming a clot, and agglutinating agent 12 binds blood cells into aggregate particles, or binds and aggregates the blood cells on a structure coated with the agglutinating agent, thereby separating the suspended blood cells from the plasma of the collected blood sample.
  • agglutinating agent 12 acting on the whole blood sample is allowed to occur through agglutinating agent 12 acting on the whole blood sample. This may be facilitated, for example, by shaking the tube to adequately mix the agglutinating agent with the whole blood sample.
  • the downstream end of primary tube 24 is inserted into upstream chamber 74 of transfer device 54.
  • tip 80 of upstream needle 78 pierces through rubber stopper 42 and upstream needle 78 is inserted through rubber stopper 42 into primary collection chamber 38 of primary tube 24.
  • a vent needle 16 may be inserted through rubber stopper 42 prior to inserting primary tube 24 into upstream chamber 74 of transfer device 54.
  • Vent needle 16 desirably includes a small gauge needle with an air permeable vent filter 18 attached on the end opposite needle tip 20. Vent needle 16 provides for venting of the pressure in primary collection chamber 38 by equilibrating the air pressure inside primary collection chamber 38 with atmospheric air pressure.
  • secondary tube 124 is inserted into downstream chamber 76 of transfer device 54.
  • tip 84 of downstream needle 82 pierces through rubber stopper 142 and downstream needle 82 is inserted through rubber stopper 142 into secondary collection chamber 138 of secondary tube 124.
  • Rubber needle sheath 88 covering downstream needle 82 is pushed by top surface 144 of rubber stopper 142 of secondary tube 124, whereby an airtight seal exists between needle sheath 88 and top surface 144 of rubber stopper 142.
  • the atmospheric equilibrated air pressure inside primary collection chamber 38 facilitates the transfer of the plasma through porous filter 72 into secondary collection chamber 138 by the reduced pressure of secondary tube 124.
  • the resulting plasma specimen inside secondary collection chamber 138 is contaminant-free and ready for subsequent transfer for diagnostic analysis.
  • FIGS. 4-13 depict further embodiments of the present invention, and include many components which are substantially identical to the components of FIGS. 1-3 . Accordingly, similar components performing similar functions will be numbered identically to those components of FIGS. 1-3 , except that a suffix "a” will be used to identify those similar components in FIGS. 4-6 , a suffix "b” will be used to identify those similar components in FIGS. 7-9 , and a suffix "c” will be used to identify those similar components in FIGS. 10-13 .
  • collection tube 90 comprises a hollow cylindrical tube including generally cylindrical tubular wall 92 extending between a first open end 94 and a second open end 95.
  • First and second open ends 94 and 95 are hermetically-sealed with rubber stoppers 42a and 42a', respectively, such as rubber stopper 42 as previously described herein.
  • Tubular wall 92 has interior surface 96 and exterior surface 98.
  • Collection tube 90 is comprised of suitable material which is impermeable to gas and liquid, and is desirably made of glass or molded plastic.
  • vent needle 16a is provided for use with rubber stopper 42a of collection tube 90.
  • rubber stoppers 42a, 42a' are hermetically sealed at circumferential surface 49a, 49a' of depending portion 50a, 50a' to interior surface 96 at the first open upstream end 94 and the second open downstream end 95 of collection tube 90.
  • Cylindrical porous filter 100 is positioned within collection tube 90 and affixed along circumferential surface 102 of filter 100 to interior surface 96 of collection tube 90.
  • Porous filter 100 is positioned so that downstream surface 104 of filter 100 abuts up against depending portion 50a' of downstream rubber stopper 42a'. Abutting porous filter 100 against downstream rubber stopper 42a' encloses cavity 52a' of depending portion 50a' of rubber stopper 42a'.
  • the interior surface 96 of collection tube 90 between interior surface 51a of cavity 52a of depending portion 50a of upstream rubber stopper 42a and upstream surface 106 of porous filter 100 define primary collection chamber 38a of primary collection tube 90.
  • anticoagulant 14a is coated on interior surface 96 of tube 92, and agglutinating agent 12a is deposited inside primary collection chamber 38a of primary tube 90.
  • transfer device 54a includes plastic cylinder 56a which includes a solid partition 57 positioned inside cylinder 56a equidistant from the opposing ends of cylinder 56a.
  • Cylinder 56a has exterior surface 58a and interior surface 60a.
  • Cylinder 56a has an interior diameter that is larger than the diameters of primary collection tube 90 and secondary tube 124a.
  • Solid partition 57 is shaped as a solid bi-convex disk, which is molded to interior surface 60a along the circumferential surface of the partition during manufacture of cylinder 56a.
  • Upstream surface 59 and downstream surface 61 of partition 57 and interior surface 60a of cylinder 56a define upstream chamber 74a and downstream chamber 76a of transfer device 54a, respectively.
  • Double-ended needle 85 is mounted in solid partition 57. Double-ended needle 85 has upstream portion 79 with upstream tip 80a and downstream portion 83 with downstream tip 84a. Double-ended needle 85 is mounted in partition 57 such that upstream portion 79 and downstream portion 83 are centrally located within transfer device 54a. Double-ended needle 85 provides fluid communication through solid partition 57.
  • Rubber needle sheaths 86a, 88a are provided to cover upstream tip 80a and downstream tip 84a, respectively, as described above.
  • blood is collected in primary collection chamber 38a of primary collection tube 90 through standard venous collection practices in a similar manner as described above.
  • the reduced pressure within the evacuated primary collection chamber 38a decreases as the volume of blood in primary collection chamber 38a increases.
  • the blood is exposed to agglutinating agent 12a deposited therein and anticoagulant 14a coated on interior surface 34a of primary collection chamber 38a. Agglutinating agent 12a assisted by anticoagulant 14a creates aggregate particles, thereby separating the suspended blood cells from the plasma component of the blood sample.
  • the downstream end of primary collection tube 90 is inserted into upstream chamber 74a of transfer device 54a, whereby upstream tip 80a of upstream portion 79 of double-ended needle 85 pierces through the downstream rubber stopper 42a' of primary collection tube 90 and upstream portion 83 of double-ended needle 85 inserts into cavity 52a' within depending portion 50a' between rubber stopper 42a' and filter 100.
  • vent needle 16a may be inserted through upstream rubber stopper 42a of primary collection tube 90 to equilibrate the air pressure inside primary collection chamber 38a with atmospheric air pressure.
  • rubber needle sheath 86a of upstream portion 79 of double-ended needle 85 is forced to slide along upstream portion 79 of needle 85 towards partition 57.
  • the tip end of sheath 86a maintains contact with top surface 44a' of downstream rubber stopper 42a' creating a near airtight seal between rubber needle sheath 86a and top surface 44a' of rubber stopper 42a'.
  • upstream portion 79a of double-ended needle 85 is fully inserted, tip 80a of upstream portion 79 of double-ended needle 85 is positioned within cavity 52a' of depending portion 50a' of rubber stopper 42a' without becoming embedded in porous filter 100. Thereafter, the upstream end of a secondary tube 124a is inserted into downstream chamber 76a of transfer device 54a, whereby tip 84a of downstream portion 83 of double-ended needle 85 pierces through rubber stopper 142a of secondary tube 124a and downstream portion 83 of double-ended needle 85 is inserted into secondary collection chamber 138a.
  • the reduced pressure inside secondary collection chamber 138a creates a pressure differential that draws the agglutinated blood in primary collection chamber 38a towards and into the porous filter 100 within the primary collection tube 90.
  • Porous filter 100 blocks passage of the aggregate particles but allows the plasma to pass through into double-ended needle 85, and then into secondary collection chamber 138a of secondary tube 124a.
  • vent needle 16a if optionally used, equilibrates the pressure inside primary collection chamber 38a with atmospheric air.
  • the resulting plasma specimen drawn into secondary collection chamber 138a is contaminant-free and ready for subsequent transfer for diagnostic analysis.
  • FIGS. 7 through 9 depict a further embodiment of the invention including primary tube 24b hermetically sealed with rubber stopper 42b.
  • Tube 24b includes generally cylindrical tubular wall 28b extending between closed end 30b and open end 32b.
  • Tube 24b has interior surface 34b and exterior surface 36b.
  • Tube 24b is similar in construction to tube 24 described above, and may be comprised of a suitable material which is impermeable to gas and liquid, and is desirably made of glass or molded plastic.
  • Porous filter 200 is provided within tube 24b.
  • Porous filter 200 is annular in shape, extending between upstream end 202 and downstream end 204, with central bore 206 extending through the length of filter 200.
  • Outer circumferential surface 208 of porous filter 200 is affixed to interior surface 34b of primary tube 24b.
  • a rubber one-way valve 210 is provided in sealed relation with upstream end 202 of porous filter 200 at the upstream opening of central bore 206.
  • One-way valve 210 allows blood to flow in only one direction, through central bore 206 and into primary collection chamber 38b of primary tube 24b, while preventing back flow of blood into central bore 206 from primary collection chamber 38b of primary tube 24b.
  • one-way valve 210 may be a "duck-bill" type valve, which permits flow of fluid in only one direction, or may be a self-sealing membrane which permits puncturing therethrough.
  • Rubber stopper 42b as previously discussed herein, is provided having depending portion 50b, which is sealed along circumferential surface 49b to interior surface 34b of the downstream end of primary tube 24b. Downstream end 204 of porous filter 200 abuts against depending portion 50b of rubber stopper 42b, closing cavity 52b. Interior surface 34b of primary tube 24b and upstream end 202 of porous filter 200 having one-way valve 210 affixed thereto define primary collection chamber 38b of primary tube 24b.
  • anticoagulant 14b Prior to affixing porous filter 200 to interior surface 34b of primary tube 24b, anticoagulant 14b is coated on interior surface 34b of the tube and agglutinating agent 12b is deposited inside the primary collection chamber 38b.
  • blood collection from a patient is accomplished by insertion of a blood collection needle during a standard procedure through rubber stopper 42b and into central bore 206. Blood can then be drawn into the space within central bore 206 and pass through one-way valve 210 and into primary collection chamber 38b based on the reduced pressure within primary collection chamber 38b. More desirably, the blood collection needle is inserted into and through one-way valve 210, such that blood can be collected from the patient and directly into primary collection chamber 38b based on the reduced pressure therein.
  • One-way valve 210 maintains the blood sample in primary collection chamber 38b of primary tube 24b.
  • downstream end of primary tube 24b is inserted into upstream chamber 74b of transfer device 54b, whereby tip 80b of upstream portion 79b of double-ended needle 85b pierces through rubber stopper 42b.
  • Upstream tip 80b of needle 85b is only inserted until it reaches a position such that upstream tip 80b is positioned within central bore 206 of annular porous filter 200.
  • downstream tip 84b of downstream portion 83b of double-ended needle 85b pierces through rubber stopper 142b of secondary tube 124b and downstream portion 83b of needle 85b inserts into secondary collection chamber 138b.
  • tip 84b of downstream portion 83b of needle 85b pierces through rubber stopper 142b
  • the reduced pressure inside secondary collection chamber 138b creates a force or pressure differential that draws the agglutinated blood from primary collection chamber 38b into porous filter 200, whereby the aggregate particles become stuck in filter 200.
  • the plasma passes through the upstream face end 202 and into central bore 206 of filter 200, through double-ended needle 85b, and into secondary collection chamber 138b of secondary tube 124b.
  • the resulting plasma specimen inside secondary collection chamber 124b is contaminant-free and ready for subsequent transfer for diagnostic analysis.
  • collection tube 90c comprises an evacuated hollow cylindrical tube including generally cylindrical tubular wall 92c extending between a first open end 94c and a second open end 95c.
  • First and second open ends 94c and 95c are hermetically sealed with rubber stoppers 42c and 42c', respectively, such as rubber stopper 42 as previously described herein.
  • Tubular wall 92c has interior surface 96c and exterior surface 98c.
  • Collection tube 90c is comprised of suitable material as described above.
  • Rubber stoppers 42c, 42c' are hermetically sealed at circumferential surface 49c, 49c' of depending portion 50c, 50c' to interior surface 96c of the first open upstream end 94c and the second open downstream end 95c of collection tube 90c, as described above.
  • Cylindrical porous filter 100c is positioned within collection tube 90c and affixed along circumferential surface 102c of filter 100c to interior surface 96c of collection tube 90c. Porous filter 100c is positioned substantially centrally within collection tube 90c, desirably substantially equidistant between first and second open ends 94c and 95c.
  • the interior space within collection tube 90c between upstream surface 106c of porous filter 100c and the interior surface 51c of cavity 52c of depending portion 50c of upstream rubber stopper 42c define primary collection chamber 38c of collection tube 90c.
  • the interior space within collection tube 90c between downstream surface 104c of porous filter 100c and the interior surface 51c' of cavity 52c' of depending portion 50c' of downstream rubber stopper 42c' define an ancillary chamber or secondary collection chamber 238, also within collection tube 90c.
  • Anticoagulant 14c is coated on interior surface 96c of the portion of collection tube 90c upstream of porous filter 100c defining primary collection chamber 38c, and agglutinating agent 12c is deposited inside such space defining primary collection chamber 38c.
  • blood is collected in primary collection chamber 38c of evacuated collection tube 90c by standard intravenous collection practices through insertion of a standard blood collection needle through upstream rubber stopper 42c.
  • Such whole blood is exposed to anticoagulant 14c and agglutinating agent 12c deposited therein.
  • the blood cells Upon entering primary collection chamber 38c, the blood cells begin to form aggregate particles.
  • the reduced pressure within primary collection chamber 38c decreases, that is, the pressure increases.
  • the separation established within collection tube 90c through porous filter 100c permits the blood to congregate, with the aggregated blood cells collecting on the upstream surface 106c of porous filter 100c, forming a partial blocking of air.
  • a transfer device 54c may be used, as shown in FIG. 13 .
  • the downstream end of collection tube 90c is inserted into an upstream chamber 74c of transfer device 54c, whereby upstream tip 80c of upstream portion 79c of needle 85c pierces through downstream rubber stopper 42c' and upstream portion 79c of needle 85c slides into the ancillary chamber provided through secondary chamber 238.
  • a further evacuated container or tube such as tube 124c can then be inserted into downstream chamber 76c of transfer device 54c as described above.
  • the plasma within the ancillary chamber defined by secondary collection chamber 238 is then drawn through double-ended needle 85c into tube 124c, and is contaminant-free and ready for subsequent transfer for diagnostic analysis.
  • the present invention provides an effective and simple method for separating plasma from a whole blood sample without the risk of contamination through opening of the containers. Portions of the assembly of the present invention can be supplied together as a kit of parts, thereby facilitating the method of transfer embodied within the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Ecology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Sampling And Sample Adjustment (AREA)

Claims (21)

  1. Dispositif pour séparer le plasma du sang entier, comprenant:
    une chambre de collection primaire évacuée (38) incluant une fermeture perforable (42) à l'une de ses extrémités;
    une chambre de collection secondaire évacuée (138);
    un filtre poreux (72) (100) (200) séparant ladite chambre de collection primaire (38) de ladite chambre de collection secondaire (138), ledit filtre poreux (72) (100) (200) ayant une taille des pores conçue pour permettre le passage de plasma à travers lui tout en prévenant le passage à travers lui de cellules sanguines liées; et
    un agent d'agglutination sanguine (12);
    caractérisé en ce que
    l'agent d'agglutination sanguine (12) se trouve au sein de ladite chambre de collection primaire (38).
  2. Dispositif selon la revendication 1, dans lequel l'agent d'agglutination (12) comprend une lectine.
  3. Dispositif selon la revendication 2, dans lequel l'agent d'agglutination (12) est choisi dans le groupe consistant en la lectine de pomme de terre, la lectine de germe de blé et des mélanges de celles-ci.
  4. Dispositif selon la revendication 1, dans lequel l'agent d'agglutination (12) comprend une structure enrobée avec un agent d'agglutination (12).
  5. Dispositif selon la revendication 4, dans lequel la structure est une microbille.
  6. Dispositif selon la revendication 1, dans lequel la chambre de collection primaire (38) contient en outre un anticoagulant (14).
  7. Dispositif selon la revendication 1, dans lequel le filtre poreux (72) (100) (200) comprend un matériau choisi dans le groupe consistant en le polyéthylène haute densité et le polypropylène haute densité.
  8. Dispositif selon la revendication 1, dans lequel la taille des pores du filtre poreux (72) (100) (200) est supérieure à 10 micromètres.
  9. Dispositif selon la revendication 1, dans lequel une différence de pression établie entre la chambre de collection secondaire (138) et la chambre de collection primaire (38) permet le passage de plasma à travers ledit filtre poreux (72) tout en prévenant le passage à travers lui de cellules sanguines liées.
  10. Dispositif selon la revendication 9, comprenant en outre une buse de ventilation conçue pour établir un équilibre de pression entre la chambre de collection primaire (38) et la pression atmosphérique pendant le passage de plasma de la chambre de collection primaire (38) à la chambre de collection secondaire (138).
  11. Dispositif selon la revendication 10, dans lequel la buse de ventilation comprend un élément aiguille (16) pour perforer la fermeture perforable (42) du récipient de collection primaire (24).
  12. Dispositif selon la revendication 1, dans lequel la chambre de collection primaire (38c) et la chambre de collection secondaire (238) comprennent une seule structure de récipient de collection (90c) contenant le filtre poreux (100c) séparant la chambre de collection primaire (38) de la chambre de collection secondaire (138).
  13. Dispositif selon la revendication 12, dans lequel la fermeture perforable (42) est attachée à une extrémité du seul récipient de collection, fermant par ce moyen la chambre de collection primaire (38), comprenant en outre une fermeture secondaire attachée à l'autre extrémité du récipient de collection, fermant par ce moyen la chambre de collection secondaire (138).
  14. Dispositif selon la revendication 13, dans lequel la fermeture secondaire est perforable.
  15. Dispositif selon la revendication 1, dans lequel la chambre de collection primaire (38) comprend un récipient de collection primaire (24) incluant une fermeture perforable (42) à l'une de ses extrémités, et la chambre de collection secondaire (138) comprend un récipient de collection secondaire (124) séparé incluant une fermeture perforable (142) à l'une de ses extrémités.
  16. Dispositif selon la revendication 15, dans lequel le filtre poreux (72) séparant la chambre de collection primaire (38) de la chambre de collection secondaire (138) est accommodé au sein d'un boîtier de passage (54) séparé.
  17. Dispositif selon la revendication 16, dans lequel le boîtier de passage (54) comprend un premier élément aiguille (78) pour perforer la fermeture perforable (42) du récipient de collection primaire (24) et un second élément aiguille (82) pour perforer la fermeture perforable (142) du récipient de collection secondaire (124), le premier élément aiguille (78) et le second élément aiguille (82) créant une communication fluide entre le récipient de collection primaire (24) et le récipient de collection secondaire (124) à travers le filtre poreux (72).
  18. Dispositif selon la revendication 17, dans lequel le boîtier de passage (54) comprend une structure (56) pour supporter le récipient de collection primaire (24) et le récipient de collection secondaire (124) quand le premier élément aiguille (78) et le second élément aiguille (82) perforent les fermetures perforables (42) (142) respectives de ceux-ci.
  19. Dispositif selon la revendication 17, comprenant en outre une première gaine perforable (86) s'étendant sur le premier élément aiguille et une seconde gaine perforable (88) s'étendant sur le second élément aiguille.
  20. Dispositif selon la revendication 15, dans lequel le récipient de collection primaire (90) inclue une fermeture perforable (42a) à l'une de ses extrémités et une fermeture perforable additionnelle (42a') à l'autre de ses extrémités, et dans lequel le filtre poreux (100) est maintenu au sein du récipient de collection primaire (90).
  21. Dispositif selon la revendication 15, dans lequel le filtre poreux comprend un filtre annulaire (200) maintenu au sein du récipient de collection primaire (24b) adjacent à sa fermeture perforable (42b), et dans lequel le récipient comprend en outre une valve à sens unique (210) permettant l'écoulement sanguin dans la chambre de collection primaire (38b) à travers la valve à sens unique (210).
EP04814676A 2003-12-24 2004-12-17 Tube pour plasma a la demande Active EP1697743B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53250903P 2003-12-24 2003-12-24
PCT/US2004/042525 WO2005066627A1 (fr) 2003-12-24 2004-12-17 Tube pour plasma a la demande

Publications (2)

Publication Number Publication Date
EP1697743A1 EP1697743A1 (fr) 2006-09-06
EP1697743B1 true EP1697743B1 (fr) 2009-03-11

Family

ID=34748805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04814676A Active EP1697743B1 (fr) 2003-12-24 2004-12-17 Tube pour plasma a la demande

Country Status (10)

Country Link
US (1) US7500569B2 (fr)
EP (1) EP1697743B1 (fr)
JP (1) JP2007518978A (fr)
CN (1) CN1910455B (fr)
AU (1) AU2004312828B2 (fr)
BR (1) BRPI0418114A (fr)
CA (1) CA2550838C (fr)
DE (1) DE602004019969D1 (fr)
ES (1) ES2321842T3 (fr)
WO (1) WO2005066627A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3890066B2 (ja) * 2005-06-27 2007-03-07 積水化学工業株式会社 血液分離器具及び血液分離装置
US8137626B2 (en) * 2006-05-19 2012-03-20 California Institute Of Technology Fluorescence detector, filter device and related methods
WO2008036614A1 (fr) 2006-09-18 2008-03-27 California Institute Of Technology Appareil de détection de molécules cibles et procédés associés
KR100920914B1 (ko) * 2009-05-09 2009-10-12 주식회사 무한기업 분리가능한 원심분리기용 시험관
FR2952069B1 (fr) * 2009-11-04 2013-06-28 Metagenex Dispositif et procede pour isoler et/ou cultiver des cellules vivantes sur filtre ou extraire leur materiel genetique
CN102435487A (zh) * 2010-09-29 2012-05-02 无锡奥克丹生物科技有限公司 小型测试仪器的试剂容器
JP5401481B2 (ja) * 2011-01-26 2014-01-29 株式会社日立ハイテクノロジーズ キャップおよび検体分注装置
WO2014019255A1 (fr) * 2012-07-31 2014-02-06 上海科华检验医学产品有限公司 Tube de collecte de sang sous vide capable de séparation directe du sérum et procédé associé
CN102772215A (zh) * 2012-08-10 2012-11-14 上海科华检验医学产品有限公司 一种可直接分离血清的真空采血管及其方法
CN102764133A (zh) * 2012-08-10 2012-11-07 上海科华检验医学产品有限公司 一种可直接分离血浆的真空采血管及其方法
EP2925853B1 (fr) * 2012-11-30 2019-07-24 Rarecyte, Inc. Système collecte d'une matière cible
US9386948B2 (en) 2012-12-05 2016-07-12 Theranos, Inc. Systems, devices, and methods for bodily fluid sample transport
US10248765B1 (en) 2012-12-05 2019-04-02 Theranos Ip Company, Llc Systems, devices, and methods for bodily fluid sample collection, transport, and handling
US20140323911A1 (en) * 2013-03-15 2014-10-30 Theranos, Inc. Methods and devices for sample collection and sample separation
SG11201507325XA (en) 2013-03-15 2015-10-29 Theranos Inc Methods and devices for sample collection and sample separation
ES2755490T3 (es) 2013-04-15 2020-04-22 Becton Dickinson Co Dispositivo de extracción de fluidos biológicos y sistema de separación de fluidos biológicos
CA2909359C (fr) * 2013-04-15 2018-07-10 Becton, Dickinson And Company Dispositif de collecte de fluide biologique et systeme de separation et d'analyse de fluide biologique
JP6174785B2 (ja) * 2013-04-15 2017-08-02 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 生物学的流体分離デバイスならびに生物学的流体分離および検査システム
EP2996736B1 (fr) * 2013-05-15 2019-10-30 Becton, Dickinson and Company Règlement manuel du courant pour la collecte de sang
US10883977B2 (en) 2013-12-20 2021-01-05 Spot Bioscience, Llc Whole blood separation sampling apparatus
EP3228249B1 (fr) * 2014-10-14 2019-02-06 Becton, Dickinson and Company Appareil pour mélanger et transférer du sang
EP4261523A3 (fr) 2014-10-14 2023-12-06 Becton, Dickinson and Company Gestion d'échantillon sanguin à l'aide de mousse à cellules ouvertes
US10371606B2 (en) 2015-07-21 2019-08-06 Theraos IP Company, LLC Bodily fluid sample collection and transport
JP2018536142A (ja) 2015-09-01 2018-12-06 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 試料の相を分離するためのデプスフィルトレーションデバイス
WO2017044888A1 (fr) 2015-09-09 2017-03-16 Theranos, Inc. Procédés et dispositifs de collecte et de séparation d'échantillons
CN105466722A (zh) * 2015-11-18 2016-04-06 广东联捷生物科技有限公司 一种微量取样和处理装置及应用
ES2846863T3 (es) * 2015-12-11 2021-07-29 Babson Diagnostics Inc Recipiente para muestras y método para separar suero o plasma de la sangre completa
EP3423189B1 (fr) * 2016-02-29 2022-04-06 Distek, Inc. Sonde d'échantillonnage pour essai de dissolution et similaire
JP7083345B2 (ja) * 2016-11-16 2022-06-10 クイデル コーポレーション 全血分離装置
USD845505S1 (en) * 2017-02-01 2019-04-09 Droycon Bioconcepts Inc. Microbiologically interactive growth platform
USD832455S1 (en) * 2017-02-03 2018-10-30 D. Roy Cullimore Microbiologically interactive growth platform
US11857966B1 (en) 2017-03-15 2024-01-02 Labrador Diagnostics Llc Methods and devices for sample collection and sample separation
EP4241888A3 (fr) * 2017-06-08 2023-12-27 Becton, Dickinson and Company Dispositif de séparation de fluide biologique
US11275096B2 (en) 2017-09-28 2022-03-15 Bioceryx Technologies Inc. Blood transfer devices and methods thereof
CA3099911A1 (fr) 2018-07-09 2020-01-16 Hanuman Pelican, Inc. Appareil et procedes de traitement du sang
CA3228790A1 (fr) * 2021-08-12 2023-02-16 Janine COX Appareil et procede pour eliminer des bulles d'un echantillon de fluide avec un filtre coulissant
WO2023048112A1 (fr) * 2021-09-21 2023-03-30 日東紡績株式会社 Agent de séparation des cellules sanguines pour l'analyse et procédé de séparation des cellules sanguines
CN113941384B (zh) * 2021-11-21 2022-11-01 洛阳职业技术学院 一种可应用于快速无损分析的胶囊式二次离心管

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492396A (en) * 1967-03-13 1970-01-27 Becton Dickinson Co Agglutinate separation method and apparatus
US3902964A (en) * 1971-12-13 1975-09-02 U S Medical Research And Dev I Method of and apparatus for chemically separating plasma or serum from formed elements of blood
US4424279A (en) * 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4753776A (en) * 1986-10-29 1988-06-28 Biotrack, Inc. Blood separation device comprising a filter and a capillary flow pathway exiting the filter
US4933092A (en) * 1989-04-07 1990-06-12 Abbott Laboratories Methods and devices for the separation of plasma or serum from whole blood
JPH0593721A (ja) * 1990-12-03 1993-04-16 Sanwa Kagaku Kenkyusho Co Ltd 血清・血漿分離器具
US5275731A (en) * 1991-06-28 1994-01-04 Jahn Karl H Apparatus for rapidly separating blood into filtered fractions
JPH05188053A (ja) * 1992-01-10 1993-07-27 Sanwa Kagaku Kenkyusho Co Ltd 血液から血清又は血漿成分を分離する器具
CN1065738C (zh) * 1995-08-09 2001-05-16 中国科学院大连化学物理研究所 用于临床血液成分化验分析的血浆分离器
US5981294A (en) * 1995-11-29 1999-11-09 Metrika, Inc. Device for blood separation in a diagnostic device
JP3644169B2 (ja) * 1996-12-26 2005-04-27 東洋紡績株式会社 血漿あるいは血清分離フィルターおよび血漿あるいは血清分離方法
US6506167B1 (en) * 1997-12-24 2003-01-14 I-Design Co., Ltd. Blood-collecting tubes
JP3863373B2 (ja) * 1999-03-02 2006-12-27 クオリジエン・インコーポレイテツド 生物学的流体の分離のための装置を用いる方法
US6505167B1 (en) * 1999-04-20 2003-01-07 Microsoft Corp. Systems and methods for directing automated services for messaging and scheduling
US6465202B1 (en) * 2000-02-17 2002-10-15 Biosafe Laboratories, Inc. Method for stabilizing aminotransferase activity in a biological fluid
US6659288B2 (en) * 2000-05-16 2003-12-09 Fuji Photo Film Co., Ltd. Plasma- or serum-collecting device
US6689615B1 (en) * 2000-10-04 2004-02-10 James Murto Methods and devices for processing blood samples
US20030013205A1 (en) * 2001-07-06 2003-01-16 Franz Konrad Separating device
JP3931069B2 (ja) * 2001-08-22 2007-06-13 協和メデックス株式会社 採血用具、これを用いた定量用溶液調製方法、定量用溶液調製器具及びその使用方法並びに定量用溶液を用いた定量方法
JP4191051B2 (ja) 2002-02-27 2008-12-03 三光純薬株式会社 血漿又は血清分離具

Also Published As

Publication number Publication date
US20050139547A1 (en) 2005-06-30
US7500569B2 (en) 2009-03-10
CA2550838C (fr) 2012-07-10
AU2004312828B2 (en) 2011-05-26
BRPI0418114A (pt) 2007-04-17
JP2007518978A (ja) 2007-07-12
DE602004019969D1 (de) 2009-04-23
AU2004312828A1 (en) 2005-07-21
ES2321842T3 (es) 2009-06-12
CN1910455A (zh) 2007-02-07
CN1910455B (zh) 2011-06-15
CA2550838A1 (fr) 2005-07-21
WO2005066627A1 (fr) 2005-07-21
EP1697743A1 (fr) 2006-09-06

Similar Documents

Publication Publication Date Title
EP1697743B1 (fr) Tube pour plasma a la demande
US4210623A (en) Fluid collection apparatus
EP2046499B1 (fr) Tube double épaisseur à base de membrane pour des collectes d'échantillons
CA2515576C (fr) Dispositifs de retrait de composants au cours d'une prise de sang et utilisations correspondantes
CN101189515B (zh) 血液分离器具及血液分离装置
KR900008693B1 (ko) 혈액 분리 장치
EP1793906B1 (fr) Separateur de sang et procede de separation d'une fraction liquide du sang total
JPS61144571A (ja) 液体標本の細胞状成分と非細胞状成分の自動分離装置
US20130026085A1 (en) Sample filtration assembly
WO2003064046A1 (fr) Systeme d'essai et de recueil de specimens
JP2011523078A (ja) 密閉容器サンプル採取システム用ハブ付きデュアルカニューレ型器具
WO2018094012A1 (fr) Dispositif de séparation de sang total
EP1722882B1 (fr) Dispositif de dialyse a reservoir d'air
US4209488A (en) Fluid collection apparatus
CN101389965A (zh) 快速检测装置
US6039868A (en) Blood separator system
GB2048097A (en) Fluid Filtration and Collection Apparatus
JPS6156766B2 (fr)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

17Q First examination report despatched

Effective date: 20080121

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE ES FR GB IT

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004019969

Country of ref document: DE

Date of ref document: 20090423

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2321842

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20091214

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20221122

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231124

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231122

Year of fee payment: 20

Ref country code: DE

Payment date: 20231121

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240102

Year of fee payment: 20